- Home
- PHAR vs GDYN Comparison
PHAR vs GDYN Comparison
Compare PHAR & GDYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- GDYN
- Stock Information
- Founded
- PHAR 1988
- GDYN 2006
- Country
- PHAR Netherlands
- GDYN United States
- Employees
- PHAR N/A
- GDYN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- GDYN Computer Software: Prepackaged Software
- Sector
- PHAR Health Care
- GDYN Technology
- Exchange
- PHAR Nasdaq
- GDYN Nasdaq
- Market Cap
- PHAR 798.2M
- GDYN 671.4M
- IPO Year
- PHAR N/A
- GDYN N/A
- Fundamental
- Price
- PHAR $13.70
- GDYN $8.10
- Analyst Decision
- PHAR Strong Buy
- GDYN Strong Buy
- Analyst Count
- PHAR 3
- GDYN 4
- Target Price
- PHAR $30.00
- GDYN $15.75
- AVG Volume (30 Days)
- PHAR 12.8K
- GDYN 1.5M
- Earning Date
- PHAR 07-31-2025
- GDYN 07-31-2025
- Dividend Yield
- PHAR N/A
- GDYN N/A
- EPS Growth
- PHAR N/A
- GDYN N/A
- EPS
- PHAR N/A
- GDYN 0.19
- Revenue
- PHAR $339,836,000.00
- GDYN $389,227,000.00
- Revenue This Year
- PHAR $12.88
- GDYN $21.15
- Revenue Next Year
- PHAR $8.54
- GDYN $13.96
- P/E Ratio
- PHAR N/A
- GDYN $41.99
- Revenue Growth
- PHAR 22.44
- GDYN 22.27
- 52 Week Low
- PHAR $6.73
- GDYN $7.46
- 52 Week High
- PHAR $17.08
- GDYN $25.50
- Technical
- Relative Strength Index (RSI)
- PHAR 67.43
- GDYN 37.06
- Support Level
- PHAR $12.13
- GDYN $7.46
- Resistance Level
- PHAR $12.76
- GDYN $7.99
- Average True Range (ATR)
- PHAR 0.89
- GDYN 0.39
- MACD
- PHAR 0.13
- GDYN 0.12
- Stochastic Oscillator
- PHAR 44.41
- GDYN 70.33
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.